Trained immunity in alveolar macrophages can lead to damaging lung inflammation, confirming the importance of context in this phenomenon.

Results come after positive results from a trial among people with idiopathic pulmomary disease.

A Scarborough lung cancer patient has visited Downing Street to help the Roy Castle Foundation deliver a vital message.

BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that ...

Lung cancer among never-smokers is rising worldwide. In one U.S. study of 12,000 lung cancer patients, the share of people who didn’t smoke rose from 8 to 15 percent over twenty years. A British ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

The UCLA advance opens the door to growing other vascularized organ models, including intestines and colons, providing ...

Researchers at McMaster University, Cleveland Clinic and Case Comprehensive Cancer Center have uncovered how a protein long ...

The approval of sunvozertinib, an oral irreversible EGFR inhibitor, was supported by data from the WU-KONG1B trial (ClinicalTrials.gov Identifier: NCT03974022 ). The primary efficacy population ...

An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable ...

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as ...